However, because of the complex pathogenesis and heterogeneity among different individuals, we found that sorafenib is only effective in a minority of HCC patients in a clinical 21-23, 38], and researchers have studied the expression of UHRF1 in HCC and its clinical significance. The gene discussed is UHRF1; the disease is hepatocellular carcinoma.